The Elusive Role of Airway Infection in Cystic Fibrosis Exacerbation

J Pediatric Infect Dis Soc. 2022 Sep 7;11(Supplement_2):S40-S45. doi: 10.1093/jpids/piac062.

Abstract

Cystic fibrosis (CF) pulmonary exacerbations (PEx) are clinical events that commonly result in increased treatment burden, decreased quality of life, and accelerated lung disease progression. CF PEx have historically been approached as though dealing with acute infections, and antibiotic treatments have been associated with improved outcomes. In this review, we discuss data supporting a causal role of CF airway infection in PEx as well studies that highlight our knowledge gaps in regard to PEx definitions, pathophysiology, and optimal treatment approaches. In the era of highly effective cystic fibrosis transmembrane conductance regulator modulator therapy, and the continually increasing health and longevity of persons with CF, a better understanding of PEx and further optimization of PEx antibiotic treatment approaches are needed.

Keywords: airway infection; cystic fibrosis; pulmonary exacerbation.

Publication types

  • Review

MeSH terms

  • Anti-Bacterial Agents / therapeutic use
  • Cystic Fibrosis* / complications
  • Cystic Fibrosis* / drug therapy
  • Humans
  • Lung
  • Quality of Life
  • Thorax

Substances

  • Anti-Bacterial Agents